IBSA will attend the 29th Annual EAU Congress (http://www.eaustockholm2014.org/) with a Satellite Symposium scheduled on Saturday, April 12th, from 18.00 to 19.30 (room A11). Please find the final program here. At this occasion, a special focus will be made on GAGs therapy with IALURIL®.
In addition, we will also have a stand in the exhibition hall (stand no. B:08:09) where we’ll be glad to meet our partners and new contacts interested in our product in the urology field.
IBSA will attend the 6th Meeting of the Study in Multidisciplinary Pain Research (http://www.simpar.eu/simpar/), in co-partnership with IBSA Italy, with a Satellite Symposium scheduled on Friday, March 28th from 08.45 to 09.45 (room Lancisi) and entirely dedicated to the new and innovative subcutaneous injection of diclofenac (Akis®/Dicloin®) developed by IBSA. Please find the final program here.
IBSA will be also present with a stand in the exhibition area (stand no. 6/11), where we will have the occasion to present, together with Akis®/Dicloin®, our well-known line of products in the "pain area" (Condrosulf, Sinovial and Flector).
IBSA is glad to announce its attendance to the 16th World Congress of Gynecological Endocrinology which will take place in Florence, from the 5th to the 8th of March 2014 (http://isge2014.isgesociety.com/).
IBSA will attend the event with both a Satellite Symposium and booth area.
The Satellite Symposium is scheduled for Friday, March 7, from 13h15 to 15h15 and will focus on Endocrine Disorders and Female Infertility (Symposium Program)
Pain management is becoming a more and more important theme among the scientific community in the different medical disciplines.
For this reason, IBSA will be present at the EFIC Congress “Pain in Europe VIII” (http://www1.kenes.com/efic/), which will be held in Florence from 9 to 12 October, with a satellite symposium and a booth.
The symposium, scheduled for Friday, October 11, 12:15-13:45 (Hall E, Padiglione Spadolini) will be entirely dedicated to the pain, both in acute and chronic pathologies, and to the need of identifying the most appropriate therapeutic approach for a tailor-made treatment (Program).
IBSA’s portfolio dedicated to the pain management will be presented at the booth during the congress.
This includes Sinovial®, Flector® and the new and innovative injectable formulation of diclofenac whose peculiarity is the reduced volume (1 ml) which allows the subcutaneous administration.
Among the activities dedicated to the field of OA, IBSA gladly announces its presence at the International Symposium Intra Articular Treatment (ISIAT) which will take place in Barcelona, October 3rd to 5th, 2013 (http://www.isiat.it/). IBSA will attend the event with both a Satellite Symposium and booth area.
The Satellite Symposium is scheduled for Friday, October 4th, 2013, from 12.30 to 13.00 (Plenary Room) and it will focus on the importance of an accurate intra-articular hyaluronic acid treatment (with the use of ultrasound technique) for the correct management of different joint pathologies. New data about the use of IBSA’s highly purified HA for intra-articular injection (Sinovial®) in shoulder pain will be also presented (program).
Our booth will be a further occasion to meet all our gusts.
IBSA announces its attendance to the 22nd EADV Congress, European Academy of Dermatology and Venereology, which will take place in Istanbul, October 2nd to 6th, 2013 (http://www.eadvistanbul2013.org/). The event is scheduled among this year’s medical-marketing activities dedicated to the dermatology field, in fact IBSA will be present with a booth which will feature our Betesil® and Ialuset®/Ialuset® Plus lines. The booth will be also shared with the colleagues of IBSA Farmaceutici Italia and Laboratoires Genévrier for their activities on the same topic.
IBSA continues to support and be present at the EULAR Congress, European League Against Rheumatism (www.eular.org) which will be held in Madrid from 12 to 15 June.
The main scientific activity is scheduled for Thursday, June 13, 8:15 to 9:45 (room Retiro), with a satellite symposium focused on the GAGs therapy ("GlycosAminoGlycans therapy") in OA management (Program)
Under this concept, experts in the field will highlight the main characteristics of the most relevant glycosaminoglycans (ie chondroitin sulfate and hyaluronic acid), from the mechanisms of action to the recent clinical evidences of these compounds in the OA management.
Other activities are related to IBSA’s presence in the exhibition area with a booth where the complete Company’s portfolio in the OA and pain area, recently enlarged with the new and innovative 1 ml injectable formulation of diclofenac, will be presented to the medical community